Mycoplasma Pneumonia (Atypical Pneumonia)

1. Clinical Overview

Summary

Mycoplasma pneumoniae is a cell wall-deficient bacterium representing one of the smallest free-living organisms capable of self-replication. It is the most common cause of atypical pneumonia in children and young adults, accounting for 20-40% of community-acquired pneumonia (CAP) cases in this demographic. [1,2]

The infection is characterised by an insidious onset over days to weeks, in stark contrast to the acute presentation of typical bacterial pneumonia. Cardinal features include a persistent dry cough, low-grade fever, and disproportionately mild physical examination findings despite extensive radiological consolidation. This clinical-radiological dissociation has earned the condition the colloquial term "Walking Pneumonia", as patients often remain ambulatory and functional despite significant pulmonary involvement. [3]

Microbiological Characteristics

M. pneumoniae lacks a peptidoglycan cell wall, rendering it:

• Invisible on Gram staining (no cell wall to retain crystal violet)
• Resistant to all β-lactam antibiotics (penicillins, cephalosporins, carbapenems)
• Fastidious in culture, requiring specialized Eaton agar and 2-3 weeks of incubation
• Smallest free-living organism (0.2-0.3 μm), capable of passing through bacterial filters [4]

Treatment Essentials

First-line antibiotics target ribosomal protein synthesis:

• Macrolides: Clarithromycin 500mg BD or Azithromycin 500mg OD for 5-7 days
• Tetracyclines: Doxycycline 100mg BD for 7 days (adults only, not in children less than 12 years)
• Fluoroquinolones: Levofloxacin 500mg OD (reserve for severe cases or macrolide resistance)

Critical Point: β-lactams (Amoxicillin, Co-amoxiclav, Ceftriaxone) are completely ineffective and should never be used as monotherapy. [5,6]

Extrapulmonary Manifestations (Exam High-Yield)

M. pneumoniae is a multi-system disease with significant extrapulmonary complications in 25-30% of cases:

[7,8]

Clinical Pearls

"No Cell Wall = No Penicillin": The absence of peptidoglycan cell wall means β-lactams have no molecular target. This is a fundamental microbiological principle frequently tested in exams.

"Target Lesions in a Coughing Patient = Mycoplasma": Erythema multiforme with classic iris/target lesions in the context of respiratory symptoms is pathognomonic until proven otherwise.

"Worse on Film Than on Exam": Classic teaching point — chest X-ray shows extensive bilateral patchy infiltrates while the patient appears well with minimal chest signs.

Cold Agglutinins Bedside Test: Place a tube of the patient's blood in ice/refrigerator (4°C). If agglutination occurs and reverses on rewarming to 37°C, cold agglutinins are present. Positive in 50-70% of M. pneumoniae cases but non-specific.

---

2. Epidemiology

Global Burden

M. pneumoniae causes 2 million pneumonia cases annually in the United States alone, with worldwide prevalence of CAP attributable to M. pneumoniae ranging from 15-40% depending on age group and surveillance methods. [9]

[10,11]

Age Distribution

Peak age: School-aged children and young adults (5-25 years) [12]

Seasonality and Outbreaks

• All-year transmission but peaks in autumn and winter (September-February in Northern Hemisphere)
• Endemic transmission: Continuous low-level circulation in communities
• Epidemic outbreaks: Every 3-7 years, lasting 6-12 months, with attack rates up to 50-70% in closed populations
• Closed communities: Schools, universities, military barracks, prisons, nursing homes [13]

Geographic Variation in Macrolide Resistance

Critical Emerging Trend: Macrolide-resistant M. pneumoniae (MRMP) rates vary dramatically by region:

Point mutation at positions 2063/2064 in the 23S rRNA gene confers macrolide resistance. [14,15]

Transmission Dynamics

• Mode: Respiratory droplet spread from close, prolonged contact (> 1 hour)
• Incubation Period: 2-3 weeks (significantly longer than typical bacterial pneumonia, which is 1-3 days)
• Infectious Period: 7-10 days before symptom onset to 14 days after (prolonged shedding)
• Attack Rate: 50% in household contacts; 70% in closed institutional outbreaks
• No Carrier State: Unlike Streptococcus pneumoniae, there is no asymptomatic nasopharyngeal carriage [16]

---

3. Aetiology and Pathophysiology

Microbiological Classification

Mycoplasma pneumoniae belongs to the class Mollicutes ("soft skin"), reflecting the absence of a rigid cell wall.

[17]

Molecular Pathogenesis

1. Attachment Phase

M. pneumoniae attaches to ciliated respiratory epithelial cells via specialized adhesion molecules:

• P1 adhesin protein (169 kDa): Primary attachment molecule, binds to sialylated glycoproteins and sulfated glycolipids on epithelial cell surface
• P30 and P116 proteins: Co-accessory adhesins
• Tip organelle: Specialized polar structure concentrating adhesins for maximum binding efficiency [18]

Exam Detail: Molecular Mechanism: The P1 adhesin undergoes antigenic variation through intragenomic recombination, allowing evasion of host immune responses and explaining recurrent infections in the same individual.

2. Colonization and Direct Cytotoxicity

Once attached, M. pneumoniae induces ciliary dysfunction and epithelial cell damage through:

• Hydrogen peroxide (H₂O₂) production: Directly toxic to respiratory epithelium
• Superoxide radicals: Oxidative stress-mediated cellular injury
• CARDS toxin (Community-Acquired Respiratory Distress Syndrome toxin): ADP-ribosylating toxin that disrupts ciliary function and induces vacuolization
• Surfactant degradation: Lipase activity reduces surfactant function, contributing to atelectasis [19]

3. Immune-Mediated Pathology

Critical Concept: The majority of M. pneumoniae disease manifestations are immune-mediated rather than direct bacterial invasion.

Innate Immunity:

• Pattern recognition receptors (TLR2, TLR6) detect mycoplasmal lipoproteins
• Activation of NF-κB and MAPK pathways
• Release of pro-inflammatory cytokines: IL-1β, IL-6, IL-8, TNF-α
• Neutrophil and macrophage recruitment to airways [20]

Adaptive Immunity:

• Antibody-mediated: IgM and IgG responses to P1 and other surface proteins
• T-cell mediated: CD4+ Th1 responses with IFN-γ production
• Autoantibody formation: Molecular mimicry between mycoplasmal antigens and host tissues (e.g., brain tissue, RBC I-antigen) → autoimmune complications [21]

4. Extrapulmonary Dissemination

M. pneumoniae is primarily a respiratory pathogen but can cause extrapulmonary disease through:

1. Direct invasion: Rare; organism detected in CSF, synovial fluid, pericardial fluid by PCR
2. Immune complex deposition: Vasculitis-like syndrome
3. Molecular mimicry: Cross-reactive antibodies attack host tissues
4. Cytokine storm: Systemic inflammatory response syndrome (SIRS) [22]

Exam Detail: Pathophysiology of Cold Agglutinins:

• M. pneumoniae infection induces IgM antibodies that recognize the I-antigen on red blood cells
• These IgM antibodies bind RBCs optimally at 4°C (cold agglutinins)
• Agglutination occurs in peripheral circulation (cooler extremities)
• Complement activation → extravascular haemolysis in liver/spleen
• Coombs test positive (detects complement C3d on RBC surface)
• Self-limiting in most cases; severe haemolysis rare (less than 5% of cases)

---

4. Clinical Presentation

Timeline of Illness

[23]

Pulmonary Manifestations

Symptoms

[24]

Physical Examination Findings

Classic Paradox: Minimal chest signs despite extensive radiological consolidation

Key Point: Up to 30% of patients have completely normal chest examination despite bilateral infiltrates on imaging. [25]

Extrapulmonary Manifestations (25-30% of Cases)

Dermatological (Common)

1. Erythema Multiforme (7-10% of cases)

• Target/Iris lesions: Concentric rings with central clearing, peripheral erythema
• Distribution: Symmetrical, acral (hands, feet, elbows, knees)
• Mucous membrane involvement: Oral ulcers in 50%
• Typically appears 7-14 days after respiratory symptoms
• Self-limiting: Resolves in 2-4 weeks without scarring [26]

2. Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (Rare, less than 1%)

• Severe mucocutaneous reaction with > 10% body surface area involvement
• Mucosal erosions: Oral, ocular, genital
• Emergency: Requires dermatology, ophthalmology, ICU care
• Mortality 5-10% (SJS) to 30-40% (TEN)
• M. pneumoniae-induced rash and mucositis (MIRM): Recently described entity distinct from classic SJS, with prominent mucositis but minimal skin detachment [27]

3. Other Rashes

• Maculopapular eruptions (10-15%)
• Urticaria (5%)
• Vesicular lesions (less than 5%)

Haematological

Cold Agglutinin Haemolytic Anaemia (30-60% subclinical, 5-10% symptomatic)

• IgM antibodies to RBC I-antigen
• Bedside test: Blood clumps at 4°C, disperses at 37°C
• Laboratory findings:
  • "Haemoglobin: Variable drop (7-12 g/dL in symptomatic cases)"
  • Reticulocytosis (5-15%)
  • Elevated LDH (> 500 U/L) and unconjugated bilirubin
  • "Direct Coombs test: Positive for C3d, negative for IgG"
• Management: Keep patient warm, avoid cold exposure; severe cases may require steroids or transfusion [28]

Otological

Bullous Myringitis (2-5% of cases)

• Haemorrhagic bullae on tympanic membrane
• Severe otalgia (ear pain) out of proportion to findings
• Examination: Otoscopy reveals blood-filled vesicles on TM
• Classic exam buzzword — highly suggestive of M. pneumoniae
• Self-limiting; bullae rupture spontaneously in 48-72 hours [29]

Neurological (0.1-7% of cases)

Spectrum of CNS Involvement:

Prognosis: 20% have permanent neurological sequelae; mortality 5-10% in encephalitis [30,31]

Cardiac (1-8.5% of cases)

[32]

Musculoskeletal

• Polyarthritis: Migratory, asymmetrical, large joints (knees, ankles); self-limiting
• Myalgia: Common (60%), can be severe
• Rhabdomyolysis: Rare; elevated CK (> 1000 U/L), myoglobinuria [33]

Gastrointestinal

• Nausea/Vomiting: 20-30%
• Diarrhoea: 10-20%, usually mild
• Hepatitis: Elevated transaminases (ALT/AST 2-5× ULN) in 10%; clinical hepatitis rare
• Pancreatitis: Very rare [34]

---

5. Differential Diagnosis

Atypical Pneumonia Comparison

[35,36]

Typical Bacterial Pneumonia Comparison

[37]

Viral Pneumonia Differential

• COVID-19: Bilateral ground-glass opacities; fever, cough, dyspnoea; rapid antigen or PCR positive
• Influenza: Abrupt onset; high fever; myalgia; seasonal (winter); rapid antigen or PCR
• RSV: Infants/elderly; bronchiolitis pattern; wheeze prominent
• Adenovirus: Conjunctivitis, pharyngitis, pneumonia triad [38]

---

6. Investigations

Initial Bedside Tests

Blood Tests

Full Blood Count

[39]

Inflammatory Markers

Clinical Pearl: Low procalcitonin (less than 0.25 ng/mL) favours atypical pneumonia over typical bacterial pneumonia and may guide antibiotic stewardship. [40]

Cold Agglutinins

• Method: Bedside test (blood clumps at 4°C) or laboratory titre measurement
• Positive: Titre ≥1:64
• Sensitivity: 50-70% in M. pneumoniae infection
• Specificity: Low (positive in EBV, CMV, lymphoma, autoimmune disease)
• Clinical Use: Supportive but not diagnostic; positive result increases suspicion [41]

Other Blood Tests

• LDH: Elevated (> 250 U/L) if haemolysis present
• Bilirubin: Unconjugated hyperbilirubinaemia in haemolysis
• Liver Function Tests: ALT/AST may be mildly elevated (2-3× ULN) in 10-15%
• U&E: Typically normal (contrast with Legionella, which causes hyponatraemia)

Microbiology

1. Nucleic Acid Amplification Tests (NAAT) — GOLD STANDARD

PCR Detection:

• Specimens: Nasopharyngeal swab, throat swab, sputum, bronchoalveolar lavage (BAL)
• Turnaround: 2-6 hours (rapid multiplex respiratory pathogen panels available)
• Sensitivity: 90-95%
• Specificity: > 98%
• Advantages: Rapid, highly sensitive, can detect multiple pathogens simultaneously
• Limitations: Cannot distinguish active infection from prolonged shedding (PCR positive up to 6 weeks post-treatment) [42,43]

Exam Detail: Multiplex PCR Panels (e.g., FilmArray Respiratory Panel):

• Detect 15-20 respiratory pathogens simultaneously (viruses + atypical bacteria)
• Include: M. pneumoniae, C. pneumoniae, Legionella, RSV, influenza A/B, adenovirus, etc.
• Turnaround: 1 hour
• Cost-effectiveness: Debated; useful in severe CAP or ICU patients

2. Serology

IgM and IgG Antibody Detection:

• IgM: Appears 7-10 days after symptom onset; peaks at 3-6 weeks; persists 2-3 months
• IgG: Appears 14-21 days after onset; peaks at 4-8 weeks; persists indefinitely
• Diagnostic Criteria:
  • "Acute infection: IgM ≥1:16 or 4-fold rise in IgG titre (acute vs convalescent sera 2-4 weeks apart)"
  • "Past infection: IgG positive, IgM negative"
• Sensitivity: 70-80% (varies by timing of sample)
• Limitations: Retrospective diagnosis (requires convalescent sample); cross-reactivity with other mycoplasmas [44]

Clinical Use: Serology is useful for epidemiological surveillance and retrospective diagnosis but has limited utility in acute management (results too slow).

3. Culture

• Media: Eaton agar with horse serum, SP4 medium
• Growth Time: 2-3 weeks (impractical for clinical decision-making)
• Sensitivity: 60-70% (fastidious organism)
• Advantages: Allows antimicrobial susceptibility testing and molecular characterization
• Clinical Use: Research and surveillance only; not for routine diagnosis [45]

Imaging

Chest X-Ray (CXR)

Classic Patterns (frequently tested):

Distribution:

• Unilateral: 60-70% of cases (lower lobes > upper lobes)
• Bilateral: 30-40% (suggests more severe disease) [46]

Key Exam Point: Clinical-radiological dissociation — extensive CXR changes with minimal clinical signs is the hallmark of atypical pneumonia.

CT Chest (if complications suspected)

Indications:

• Severe or progressive disease despite treatment
• Suspected complications (pleural effusion, empyema, necrotizing pneumonia)
• Immunocompromised patients
• Differential diagnosis uncertainty

CT Findings:

• Ground-glass opacities: Multifocal, bilateral
• Centrilobular nodules: "Tree-in-bud" pattern (bronchiolar inflammation)
• Bronchial wall thickening: Prominent airways
• Consolidation: Patchy, peribronchovascular distribution
• Pleural effusion: Usually small volume
• Necrotizing pneumonia: Rare; low-attenuation areas within consolidation [47]

---

7. Management

Risk Stratification: CURB-65 Score

Apply CURB-65 to all CAP patients, including suspected M. pneumoniae:

Management Based on Score:

• 0-1: Low severity → Outpatient treatment with oral antibiotics
• 2: Moderate severity → Consider hospital admission for monitoring
• ≥3: High severity → Hospital admission, consider ICU if score ≥4 [48]

Antibiotic Therapy

First-Line: Macrolides

Mechanism: Inhibit bacterial protein synthesis by binding to 50S ribosomal subunit (23S rRNA)

Paediatric Dosing:

• Azithromycin: 10 mg/kg Day 1 (max 500mg), then 5 mg/kg Days 2-5 (max 250mg)
• Clarithromycin: 7.5 mg/kg BD (max 500mg BD) [49]

Advantages:

• Excellent tissue penetration (intracellular accumulation)
• Anti-inflammatory effects (immunomodulatory)
• Generally well-tolerated

Side Effects:

• GI upset (nausea, diarrhoea) in 10-20%
• QTc prolongation (avoid in long QT syndrome, concurrent QT-prolonging drugs)
• Hepatotoxicity (rare)

Second-Line: Tetracyclines

Doxycycline:

• Dosing: 100mg BD (adults); 200mg loading dose, then 100mg OD (alternative)
• Duration: 7 days
• Mechanism: Inhibits bacterial protein synthesis (30S ribosomal subunit)
• Advantages: Effective against MRMP; once/twice daily dosing; low cost
• Contraindications: Children less than 12 years (dental staining), pregnancy (teratogenic), breastfeeding
• Side Effects: Photosensitivity (advise sun protection), oesophagitis (take with water, remain upright 30 min), nausea [50]

Third-Line: Fluoroquinolones

Levofloxacin:

• Dosing: 500mg OD (or 750mg OD for severe disease)
• Duration: 7-14 days
• Indications:
  • Macrolide-resistant M. pneumoniae (MRMP)
  • Severe disease requiring ICU admission
  • Macrolide/tetracycline allergy or contraindication
• Advantages: Broad-spectrum (covers typical + atypical bacteria); excellent bioavailability
• Side Effects: Tendinopathy/rupture (especially Achilles tendon), QTc prolongation, CNS effects (dizziness, seizures)
• Cautions: Reserve for severe cases due to antimicrobial stewardship concerns (C. difficile risk, resistance development) [51]

Moxifloxacin: 400mg OD for 7-10 days (alternative fluoroquinolone)

Management of Macrolide-Resistant M. pneumoniae (MRMP)

Clinical Suspicion:

• Fever persisting > 48-72 hours after initiating macrolide therapy
• Geographic risk factors: Travel to/residence in East Asia
• Known local MRMP prevalence > 10%

Diagnostic Confirmation:

• PCR detection of 23S rRNA mutations (positions 2063, 2064, 2617)

Treatment Algorithm for MRMP:

SUSPECTED MRMP (Persistent fever > 72h on macrolide)
                      ↓
          ┌───────────┴───────────┐
          │                       │
    MILD-MODERATE             SEVERE
    (Outpatient)          (Hospitalized, ICU)
          │                       │
    Doxycycline                Levofloxacin
    100mg BD x 7 days         500-750mg OD x 10-14 days
    (if age > 12 years)              │
          │                    + Supportive care
    Monitor response         (O₂, fluids, steroids if indicated)
          │
    If less than 12 years:
    Consider fluoroquinolone
    (weigh risks vs benefits)

Evidence: Meta-analysis shows MRMP patients have fever duration 1.7 days longer, hospitalization 1.6 days longer, and 21-fold higher risk of fever > 48h after macrolides compared to MSMP. Second-line antibiotics reduce this morbidity. [14,15]

Supportive Care

Role of Corticosteroids

Indications (controversial, not routinely recommended):

• Severe M. pneumoniae pneumonia with ARDS
• Refractory cases despite appropriate antibiotics
• Severe immune-mediated complications (e.g., encephalitis, severe haemolysis)

Evidence: Observational studies suggest corticosteroids may reduce fever duration and length of hospitalization in severe/refractory cases, but no RCTs support routine use. Potential harms include prolonged viral shedding (if co-infection) and immunosuppression. [52]

Typical Regimen (if used):

• Methylprednisolone: 1-2 mg/kg/day IV for 3-5 days, then taper
• Dexamethasone: 0.15 mg/kg/dose BD for 2-3 days

Management of Complications

Cold Agglutinin Haemolytic Anaemia

• Mild: Observation, keep patient warm (avoid cold exposure)
• Moderate-Severe (Hb less than 8 g/dL, symptomatic):
  • Warm (37°C) blood transfusion if Hb less than 7 g/dL or symptomatic anaemia
  • "Steroids: Prednisolone 1 mg/kg/day for 1-2 weeks, taper"
  • Avoid cold IV fluids, keep room warm [53]

Stevens-Johnson Syndrome / MIRM

• Dermatology consult (urgent)
• Ophthalmology consult (assess ocular involvement)
• Supportive care: Wound care, fluid/electrolyte management, nutritional support
• Discontinue potential drug triggers (NSAIDs, antibiotics if alternative available)
• ICU admission if severe (BSA > 10%, haemodynamic instability)
• IVIG: 2-3 g/kg over 3-5 days (evidence mixed, may reduce mortality)
• Avoid systemic steroids in classic SJS/TEN (increased infection risk, no proven benefit) [27]

Neurological Complications

• Encephalitis: IV aciclovir (empiric, covers HSV) + antibiotics; MRI brain; LP (CSF PCR for M. pneumoniae); consider IVIG or plasmapheresis if severe
• Guillain-Barré Syndrome: IVIG 2 g/kg over 5 days OR plasmapheresis; respiratory monitoring (FVC); intubation if bulbar weakness or FVC less than 15 mL/kg [30]

Pleural Effusion/Empyema

• Diagnostic thoracentesis: If effusion > 1cm on lateral decubitus CXR
• Light's criteria: Distinguish exudate vs transudate
• Empyema: Chest drain insertion (if pH less than 7.2, glucose less than 3.3 mmol/L, or frankly purulent)
• Antibiotics: Add anaerobic cover if empyema (e.g., co-amoxiclav or metronidazole) [54]

Duration of Therapy

Follow-Up and Monitoring

• Clinical Review: 48-72 hours after starting antibiotics (assess fever resolution, clinical improvement)
• Repeat CXR: Not routinely indicated if clinical improvement; consider if:
  • Persistent symptoms at 6 weeks (exclude malignancy, TB)
  • Severe disease or complications
  • Age > 50 years (higher risk of underlying pathology)
• Return to Normal Activities: Most patients can resume normal activities within 7-14 days, but full recovery (cough resolution) may take 4-6 weeks [55]

---

8. Prognosis and Outcomes

Overall Prognosis

[56]

Clinical Course

• Defervescence: Fever resolves within 48-72 hours of appropriate antibiotics (macrolide-sensitive strains)
• Cough Duration: 2-6 weeks (median 3-4 weeks) despite antibiotic therapy; "post-Mycoplasma cough" is common and not indicative of treatment failure
• Radiological Resolution: CXR clears in 4-8 weeks (lags behind clinical improvement) [57]

Mortality

• Overall: less than 1% in immunocompetent individuals
• With Complications:
  • "Encephalitis: 5-10%"
  • "ARDS/Respiratory Failure: 3-5%"
  • "Severe SJS/TEN: 5-30%"
• Risk Factors for Severe Disease:
  • Age > 65 years
  • Immunosuppression (HIV, transplant, chemotherapy)
  • Chronic lung disease (COPD, bronchiectasis)
  • Sickle cell disease
  • Corticosteroid therapy [58]

Long-Term Sequelae

[59]

Recurrent Infection

• Immunity: Natural infection confers limited, short-lived immunity (6-12 months)
• Recurrent Infections: Possible due to antigenic variation of P1 adhesin protein
• No Vaccine: Currently no licensed vaccine available (experimental vaccines in development) [60]

---

9. Prevention and Infection Control

Transmission Precautions

In Healthcare Settings:

• Standard Precautions: Hand hygiene, PPE (gloves, aprons) for contact with respiratory secretions
• Droplet Precautions: Surgical mask for staff within 1 meter of patient; single room if available (not mandatory)
• Duration: Until 24 hours after starting effective antibiotics [61]

Household and Close Contacts

• No Routine Chemoprophylaxis: Not recommended for household contacts
• Close Monitoring: Educate contacts to seek medical review if symptoms develop (cough, fever)
• Symptomatic Treatment: Treat contacts empirically if symptomatic (same antibiotics as index case)

Public Health Measures

• Outbreak Investigation: If institutional outbreak (school, military barracks), local public health should be notified
• Isolation of Cases: During acute illness, isolate symptomatic individuals to reduce transmission
• Hand Hygiene and Respiratory Etiquette: Cover coughs/sneezes, dispose of tissues, hand washing [62]

---

10. Evidence and Guidelines

Key Guidelines

[48,49,63,64]

Landmark Evidence

1. Macrolide Resistance Meta-Analysis (Chen et al., 2020)

• Study: Systematic review of 17 studies, 3,146 paediatric MRMP cases
• Findings: MRMP associated with 1.71 days longer fever, 1.61 days longer hospitalization, 21-fold higher risk of persistent fever > 48h on macrolides
• Conclusion: MRMP is a clinically significant problem requiring alternative antibiotics
• PMID: 32568052 [15]

2. Atypical Pneumonia Pathophysiology (Miyashita, 2022)

• Study: Comprehensive review of atypical pneumonia diagnosis/treatment
• Findings: Japanese criteria (6 parameters) can differentiate atypical from typical pneumonia with 80% sensitivity
• Conclusion: Targeted antibiotic therapy based on clinical syndrome reduces unnecessary broad-spectrum use
• PMID: 34750083 [1]

3. Extrapulmonary Manifestations (Waites & Talkington, 2004)

• Study: Review of M. pneumoniae extrapulmonary disease
• Findings: 25-30% have extrapulmonary manifestations; immune-mediated pathology predominates
• Conclusion: Clinicians should maintain high index of suspicion for multi-system involvement
• PMID: 15110799 [7]

4. Neurological Complications (Tsiodras et al., 2005)

• Study: Case series and literature review of CNS M. pneumoniae
• Findings: 0.1% of M. pneumoniae infections develop CNS complications; 20% have permanent sequelae
• Conclusion: Aggressive immunotherapy (IVIG/steroids) may improve outcomes
• PMID: 15845155 [30]

---

11. Special Populations

Pregnancy

• Risk to Mother: M. pneumoniae pneumonia can be more severe in pregnancy (physiological changes in respiratory function)
• Risk to Fetus: Rare cases of intrauterine transmission reported; adverse outcomes (preterm labour, stillbirth) associated with severe maternal pneumonia
• Treatment:
  • "First-Line: Azithromycin 500mg OD × 5 days (FDA Category B; safe in pregnancy)"
  • "Avoid: Doxycycline (teratogenic), fluoroquinolones (cartilage toxicity in animal studies)"
• Management: Low threshold for hospital admission; maintain SpO₂ > 95% (higher target than non-pregnant) [65]

Immunocompromised Patients

Populations at Risk:

• HIV/AIDS (especially CD4 less than 200)
• Solid organ transplant recipients
• Haematological malignancy
• Immunosuppressive therapy (steroids, chemotherapy, biologics)

Clinical Features:

• More severe pneumonia
• Higher risk of respiratory failure
• Prolonged shedding (weeks to months)
• Increased extrapulmonary complications

Treatment:

• Combination therapy: Macrolide PLUS fluoroquinolone (broader coverage)
• Longer duration: 14-21 days
• Low threshold for ICU admission [66]

Chronic Lung Disease (COPD, Asthma)

• M. pneumoniae as Asthma Trigger: 5-10% of asthma exacerbations associated with M. pneumoniae infection
• Chronic Colonization: Controversial; some evidence of persistent M. pneumoniae in airways of severe asthmatics
• Treatment:
  • Standard antibiotics PLUS bronchodilators (salbutamol, ipratropium)
  • Consider inhaled corticosteroids (ICS) during exacerbation
  • "Macrolide trial: Long-term azithromycin (250mg three times weekly) may reduce exacerbations in severe asthma (anti-inflammatory effects) [67,68]"

Sickle Cell Disease

• Increased Risk: Acute chest syndrome (ACS) in sickle cell patients can be triggered by M. pneumoniae (10-20% of ACS cases)
• Clinical Features: Fever, chest pain, hypoxia, new pulmonary infiltrates
• Treatment:
  • "Antibiotics: Macrolide (azithromycin) + cephalosporin (e.g., ceftriaxone) to cover typical bacteria"
  • "Supportive Care: O₂, analgesia, IV fluids, incentive spirometry"
  • "Blood Transfusion: Simple or exchange transfusion if severe hypoxia or deterioration [69]"

---

12. Patient and Layperson Explanation

What is Mycoplasma Pneumonia?

Mycoplasma pneumonia is a chest infection (pneumonia) caused by a tiny germ called Mycoplasma pneumoniae. Unlike common bacteria, this germ doesn't have a rigid cell wall, which makes it different and explains why certain antibiotics don't work against it.

This type of pneumonia is often called "Walking Pneumonia" because people usually feel well enough to walk around and continue daily activities, even though they have a lung infection. It's more common in children and young adults, especially in schools and universities where people are in close contact.

What are the Symptoms?

The main symptoms are:

• Persistent dry cough that can last for weeks
• Mild fever (usually not very high)
• Tiredness and headache (flu-like feeling)
• Sore throat
• Occasionally, a rash (red target-shaped spots) or ear pain

The cough is often the most bothersome symptom and can continue for 4-6 weeks, even after treatment.

How Did I Catch It?

Mycoplasma pneumonia spreads through droplets when an infected person coughs or sneezes. You're more likely to catch it if you spend time in close contact with someone who has it (e.g., family members, classmates). It takes about 2-3 weeks after exposure for symptoms to appear.

Why Didn't Amoxicillin Work?

Amoxicillin and other common antibiotics like penicillin work by attacking the cell wall of bacteria. Since Mycoplasma doesn't have a cell wall, these antibiotics can't damage it. That's why your doctor prescribed a different type of antibiotic (like azithromycin, clarithromycin, or doxycycline) that works in a different way — by stopping the germ from making proteins it needs to survive.

How is it Treated?

• Antibiotics: A course of azithromycin (usually 5 days) or clarithromycin (7 days) is the main treatment. These antibiotics are effective against Mycoplasma.
• Rest and Fluids: Get plenty of rest and drink lots of water.
• Paracetamol or Ibuprofen: For fever and aches.
• Cough Medicine: May help at night, but the cough will improve slowly over weeks.

Will My Cough Ever Go Away?

Yes, but it takes time. Even after the antibiotics have killed the germ, your lungs need time to heal. It's normal for the cough to persist for 2-6 weeks after finishing treatment. This doesn't mean the antibiotics didn't work — it's just part of the recovery process.

Can I Go to Work or School?

You should stay home while you have a fever or feel very unwell. Once your fever has gone and you're feeling better (usually 2-3 days after starting antibiotics), you can return to work or school, even if you still have a mild cough.

Is It Serious?

For most healthy people, Mycoplasma pneumonia is not serious and gets better with antibiotics and rest. However, in rare cases, it can cause complications like severe lung problems, rashes, or even affect the brain or heart. Contact your doctor immediately if you:

• Have difficulty breathing or severe chest pain
• Develop a severe rash with blisters
• Feel confused or have severe headaches
• Have very pale skin or dark urine (signs of anaemia)

Can I Get It Again?

Yes, you can get Mycoplasma pneumonia more than once. The body's immune response doesn't last forever, so it's possible to be infected again in the future, especially if you're exposed in an outbreak.

---

13. Examination Focus

MRCP / FRACP High-Yield Topics

Written Exam (SBA/MCQ)

1. Antibiotic Resistance to β-Lactams

• Q: "A 22-year-old student presents with a 10-day history of dry cough and low-grade fever. CXR shows bilateral patchy infiltrates. He was started on amoxicillin 5 days ago with no improvement. What is the mechanism of treatment failure?"
• A: Absence of peptidoglycan cell wall — β-lactams target cell wall synthesis; M. pneumoniae lacks this target.

2. Cold Agglutinins

• Q: "A patient with atypical pneumonia develops haemolytic anaemia. Blood sample clumps when refrigerated but disperses at 37°C. What is the antibody class responsible?"
• A: IgM antibodies to RBC I-antigen (cold agglutinins bind optimally at 4°C).

3. Extrapulmonary Manifestations

• Q: "A 15-year-old with cough and fever develops target lesions on palms and soles. Most likely organism?"
• A: Mycoplasma pneumoniae (erythema multiforme is classic association).

4. Macrolide Resistance

• Q: "A child in China with Mycoplasma pneumonia has persistent fever 72 hours after azithromycin. Next step?"
• A: Switch to doxycycline or levofloxacin (high MRMP prevalence in East Asia; 23S rRNA mutation confers resistance).

5. Neurological Complications

• Q: "A patient with recent pneumonia develops ascending paralysis and areflexia. CSF shows elevated protein but normal cell count. Diagnosis?"
• A: Guillain-Barré Syndrome (post-Mycoplasma infection; albuminocytologic dissociation on LP).

PACES / Clinical Exam Scenarios

Scenario 1: History-Taking Station

• Stem: "Take a history from a 20-year-old university student with a 2-week cough."
• Key Points to Elicit:
  • Dry vs productive cough
  • Contacts at university (outbreak setting)
  • Previous antibiotics (β-lactam failure)
  • Extrapulmonary symptoms (rash, ear pain, joint pain)
  • Functional status ("walking pneumonia" — still attending lectures?)

Scenario 2: Data Interpretation

• Results Given:
  • WCC 9.5 × 10⁹/L (normal)
  • CRP 45 mg/L (mildly elevated)
  • "CXR: Bilateral reticulonodular infiltrates"
  • "Cold agglutinins: Positive (titre 1:128)"
• Question: "What is the most likely diagnosis and appropriate antibiotic?"
• Answer: Mycoplasma pneumoniae; azithromycin or clarithromycin

Scenario 3: Communication Station

• Task: "Explain to a patient why amoxicillin didn't work and why you're changing to azithromycin."
• Key Points:
  • Simple explanation of cell wall absence
  • Reassure that azithromycin works by a different mechanism
  • Set expectations (cough may persist weeks; not treatment failure)

Viva Voce Questions and Model Answers

Q1: Why is Mycoplasma pneumoniae described as "atypical"? A: The term "atypical" refers to three key features:

1. Clinical: Insidious onset, dry cough, minimal chest signs despite extensive CXR changes (contrast with acute lobar pneumonia)
2. Microbiological: Lacks cell wall, invisible on Gram stain, requires special culture media
3. Treatment: Unresponsive to β-lactams (typical first-line for CAP); requires macrolides/tetracyclines

Q2: How would you investigate a patient with suspected Mycoplasma pneumonia? A:

• Bedside: Vital signs (oxygen saturation, temperature, RR)
• Blood Tests: FBC (normal/mild ↑WCC), CRP (mildly elevated), cold agglutinins (supportive but non-specific), LDH (if haemolysis)
• Microbiology: PCR (nasopharyngeal swab or sputum — gold standard, rapid); Serology (IgM — retrospective, useful for epidemiology)
• Imaging: CXR (reticulonodular/patchy infiltrates, often bilateral); CT chest if complications suspected
• CURB-65 score to stratify severity

Q3: Describe the pathogenesis of cold agglutinin haemolytic anaemia in Mycoplasma infection. A:

1. Immune Response: M. pneumoniae infection triggers production of polyclonal IgM antibodies
2. Molecular Mimicry: These IgM antibodies cross-react with I-antigen on RBC surface
3. Temperature-Dependent Binding: IgM binds RBCs optimally at 4°C (peripheral circulation in cool extremities)
4. Complement Activation: IgM-RBC complex activates complement → C3b deposition on RBC membrane
5. Extravascular Haemolysis: C3b-coated RBCs removed by splenic macrophages → haemolysis
6. Laboratory Findings: Coombs test positive for C3d, negative for IgG; elevated LDH, unconjugated bilirubin
7. Clinical: Usually self-limiting; severe cases managed with warmth, transfusion, steroids

Q4: When would you use corticosteroids in Mycoplasma pneumonia? A: Corticosteroids are not routinely recommended but may be considered in:

1. Severe refractory pneumonia: ARDS, respiratory failure despite appropriate antibiotics
2. Immune-mediated complications: Encephalitis, severe haemolytic anaemia, Stevens-Johnson syndrome (controversial)
3. Regimen: Methylprednisolone 1-2 mg/kg/day IV for 3-5 days, then taper
4. Cautions: No high-quality RCT evidence; potential risks (immunosuppression, prolonged shedding)

Q5: A patient from China with Mycoplasma pneumonia fails to improve on azithromycin. Why, and what would you do? A: Reason: Macrolide-resistant M. pneumoniae (MRMP) — highly prevalent in East Asia (70-90%) Mechanism: Point mutations at positions 2063/2064 in 23S rRNA gene → loss of macrolide binding Management:

1. Switch antibiotic: Doxycycline 100mg BD (if age > 12) OR Levofloxacin 500mg OD (if severe or age less than 12)
2. Duration: 7-14 days (longer for severe disease)
3. Confirm resistance: PCR for 23S rRNA mutations (if available)
4. Monitor: Fever should resolve within 48-72h of effective antibiotic

---

14. Key References

Primary Sources

1. Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022;60(1):56-67. PMID: 34750083. DOI: 10.1016/j.resinv.2021.09.009

2. Georgakopoulou VE, Lempesis IG, Tarantinos K, et al. Atypical pneumonia (Review). Exp Ther Med. 2024;28(5):424. PMID: 39301259. DOI: 10.3892/etm.2024.12713

3. Jensen PS, Halber MD, Putman CE. Mycoplasma pneumonia. CRC Crit Rev Diagn Imaging. 1980;12(4):385-415. PMID: 6767579

4. Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747-809. PMID: 28539503. DOI: 10.1128/CMR.00114-16

5. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1-iii55. PMID: 19734136. DOI: 10.1136/thx.2009.121434

6. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. PMID: 31573350. DOI: 10.1164/rccm.201908-1581ST

7. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev. 2004;15(2-3):157-168. PMID: 15110799. DOI: 10.1016/j.cytogfr.2004.01.001

8. Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23. PMID: 26870011. DOI: 10.3389/fmicb.2016.00023

9. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. PMID: 26172429. DOI: 10.1056/NEJMoa1500245

10. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis. 2001;1(5):334-344. PMID: 11871806. DOI: 10.1016/S1473-3099(01)00147-5

11. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993;17(Suppl 1):S37-46. PMID: 8399935. DOI: 10.1093/clinids/17.supplement_1.s37

12. Chalker VJ, Stocki T, Mentasti M, et al. Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012. Euro Surveill. 2012;17(6):20081. PMID: 22340977

13. Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995. Eur J Epidemiol. 1997;13(5):581-586. PMID: 9258572. DOI: 10.1023/a:1007353121693

14. Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2024;20(9):901-914. PMID: 39143259. DOI: 10.1007/s12519-024-00831-0

15. Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerg Infect Dis. 2020;26(7):1382-1391. PMID: 32568052. DOI: 10.3201/eid2607.200017

16. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis. 1979;139(6):681-687. PMID: 458415. DOI: 10.1093/infdis/139.6.681

17. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 1998;62(4):1094-1156. PMID: 9841667. PMCID: PMC98941

18. Kenri T, Seto S, Horino A, et al. Use of fluorescent-protein tagging to determine the subcellular localization of Mycoplasma pneumoniae proteins encoded by the cytadherence regulatory locus. J Bacteriol. 2004;186(19):6944-6955. PMID: 15466048. DOI: 10.1128/JB.186.20.6944-6955.2004

19. Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A. 2006;103(17):6724-6729. PMID: 16617115. DOI: 10.1073/pnas.0510644103

20. Shimizu T, Kida Y, Kuwano K. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6. J Immunol. 2005;175(7):4641-4646. PMID: 16177110. DOI: 10.4049/jimmunol.175.7.4641

21. Tsiodras S, Kelesidis I, Kelesidis T, et al. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005;51(5):343-354. PMID: 15845155. DOI: 10.1016/j.jinf.2005.07.005

22. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother. 2010;16(3):162-169. PMID: 20186455. DOI: 10.1007/s10156-010-0044-x

23. Foy HM, Kenny GE, McMahan R, et al. Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance. JAMA. 1970;214(9):1666-1672. PMID: 4320139

24. Clyde WA Jr. Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis. 1993;17(Suppl 1):S32-36. PMID: 8399934. DOI: 10.1093/clinids/17.supplement_1.s32

25. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect. 2003;9(4):263-273. PMID: 12667234. DOI: 10.1046/j.1469-0691.2003.00590.x

26. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239-245. PMID: 25592622. DOI: 10.1016/j.jaad.2014.06.026

27. Schalock PC, Dinulos JG, Pace N, et al. Erythema multiforme due to Mycoplasma pneumoniae infection in two children. Pediatr Dermatol. 2006;23(6):546-555. PMID: 17155994. DOI: 10.1111/j.1525-1470.2006.00316.x

28. Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226-231. PMID: 27913485. DOI: 10.1182/asheducation-2016.1.226

29. Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. Chest. 1989;95(3):639-646. PMID: 2645477. DOI: 10.1378/chest.95.3.639

30. Tsiodras S, Kelesidis I, Kelesidis T, et al. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005;51(5):343-354. PMID: 15845155. DOI: 10.1016/j.jinf.2005.07.005

31. Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis. 2001;32(12):1674-1684. PMID: 11360208. DOI: 10.1086/320748

32. Narita M. Cardiac involvement in Mycoplasma pneumoniae infections. Curr Opin Pulm Med. 2012;18(3):247-251. PMID: 22388583. DOI: 10.1097/MCP.0b013e32835153ca

33. Lind K. Manifestations and complications of Mycoplasma pneumoniae disease: a review. Yale J Biol Med. 1983;56(5-6):461-468. PMID: 6364894. PMCID: PMC2589975

34. Ali NJ, Sillis M, Andrews BE, et al. The clinical spectrum and diagnosis of Mycoplasma pneumoniae infection. Q J Med. 1986;58(227):241-251. PMID: 3774962

35. File TM. Community-acquired pneumonia. Lancet. 2003;362(9400):1991-2001. PMID: 14683661. DOI: 10.1016/S0140-6736(03)15021-0

36. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis. 2000;31(Suppl 2):S35-39. PMID: 10984527. DOI: 10.1086/314074

37. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619-1628. PMID: 25337751. DOI: 10.1056/NEJMra1312885

38. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377(9773):1264-1275. PMID: 21435708. DOI: 10.1016/S0140-6736(10)61459-6

39. Loens K, Beck T, Ursi D, et al. Evaluation of different serological assays for the detection of Mycoplasma pneumoniae-specific IgM antibodies in respiratory tract infections. J Med Microbiol. 2008;57(Pt 3):333-338. PMID: 18287297. DOI: 10.1099/jmm.0.47513-0

40. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066. PMID: 19738090. DOI: 10.1001/jama.2009.1297

41. Ramirez JA. Clinical and epidemiologic characteristics of atypical pneumonia. Semin Respir Infect. 2000;15(1):17-24. PMID: 10770801. DOI: 10.1053/srin.2000.0150017

42. Winchell JM, Thurman KA, Mitchell SL, et al. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol. 2008;46(9):3116-3118. PMID: 18596138. DOI: 10.1128/JCM.00389-08

43. Loens K, Ursi D, Goossens H, Ieven M. Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections. J Clin Microbiol. 2003;41(11):4915-4923. PMID: 14605116. DOI: 10.1128/JCM.41.11.4915-4923.2003

44. Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol. 2005;43(5):2277-2285. PMID: 15872256. DOI: 10.1128/JCM.43.5.2277-2285.2005

45. Kenny GE, Kaiser GG, Cooney MK, Foy HM. Diagnosis of Mycoplasma pneumoniae pneumonia: sensitivities and specificities of serology with lipid antigen and isolation of the organism on soy peptone medium for identification of infections. J Clin Microbiol. 1990;28(9):2087-2093. PMID: 2229390. PMCID: PMC268088

46. Reittner P, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol. 2000;174(1):37-41. PMID: 10628451. DOI: 10.2214/ajr.174.1.1740037

47. Tanaka H, Narita M, Teramoto S, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest. 2002;121(5):1493-1497. PMID: 12006434. DOI: 10.1378/chest.121.5.1493

48. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. PMID: 12728155. DOI: 10.1136/thorax.58.5.377

49. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-76. PMID: 21880587. DOI: 10.1093/cid/cir531

50. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002;2(9):530-538. PMID: 12206968. DOI: 10.1016/s1473-3099(02)00369-9

51. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160-2162. PMID: 19237645. DOI: 10.1128/AAC.01684-08

52. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children. Respir Care. 2015;60(10):1469-1475. PMID: 26106204. DOI: 10.4187/respcare.03920

53. Gertz MA. Cold hemolytic syndrome. Hematology Am Soc Hematol Educ Program. 2006:19-23. PMID: 17124033. DOI: 10.1182/asheducation-2006.1.19

54. Light RW. Pleural effusions. Med Clin North Am. 2011;95(6):1055-1070. PMID: 22032427. DOI: 10.1016/j.mcna.2011.08.005

55. Sopena N, Sabrià-Leal M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005;127(1):213-219. PMID: 15653987. DOI: 10.1378/chest.127.1.213

56. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, et al. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis. 2001;183(4):675-678. PMID: 11170998. DOI: 10.1086/318529

57. Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis. 2007;45(8):983-991. PMID: 17879912. DOI: 10.1086/521893

58. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134-141. PMID: 8531309

59. Meyer Sauteur PM, Jacobs BC, Spuesens EB, et al. Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS Pathog. 2014;10(6):e1003983. PMID: 24901308. DOI: 10.1371/journal.ppat.1003983

60. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956-973. PMID: 18754792. DOI: 10.1111/j.1574-6976.2008.00129.x

61. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Am J Infect Control. 2007;35(10 Suppl 2):S65-164. PMID: 18068815. DOI: 10.1016/j.ajic.2007.10.007

62. Foy HM, Grayston JT, Kenny GE, et al. Epidemiology of Mycoplasma pneumoniae infection in families. JAMA. 1966;197(11):859-866. PMID: 5952928

63. National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Clinical guideline [NG138]. Published December 2014, updated 2023. https://www.nice.org.uk/guidance/ng138

64. Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2024;20(9):901-914. PMID: 39143259. DOI: 10.1007/s12519-024-00831-0

65. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005;33(10 Suppl):S390-397. PMID: 16215359. DOI: 10.1097/01.ccm.0000182483.24836.66

66. Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol. 2009;41(3):159-166. PMID: 19664530. DOI: 10.1016/j.pediatrneurol.2009.04.012

67. Carr TF, Kraft M. Chronic infection and severe asthma. Immunol Allergy Clin North Am. 2016;36(3):483-502. PMID: 27401621. DOI: 10.1016/j.iac.2016.03.010

68. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659-668. PMID: 28687413. DOI: 10.1016/S0140-6736(17)31281-3

69. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855-1865. PMID: 10861320. DOI: 10.1056/NEJM200006223422502

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. All clinical decisions must account for individual patient circumstances, local protocols, and antimicrobial resistance patterns. Always consult appropriate specialists and refer to the latest evidence-based guidelines. This content does not replace clinical judgment or professional medical advice.